Previously, we observed that (i) androgen signaling promotes ovarian cancer development9, and (ii) CSF1/CSF1R and ErbB4 proteins were overexpressed in the ovarian tissues of HR women compared to LR, and this overexpression was reversed in those HR women treated with flutamide9,10. This evidence concerns the gene ERBB4 and ovarian carcinoma.